期刊文献+

盐酸利匹韦林顺式异构体Z和杂质X的合成与表征

Synthesis and Characterization of cis-Isomer Z and Impurity X of Rilpivirine Hydrochloride
下载PDF
导出
摘要 以(E)-3-(4-氨基-3,5-二甲基苯基)丙烯腈为起始物料,通过在氨基氮原子上引入三氟乙酰基等吸电子基团,可以合成较多的盐酸利匹韦林顺式异构体Z(约占50%)和杂质X(约占5%),其结构经1HNMR、13CNMR和MS等确证,并通过HPLC检测其纯度均达到98%以上,杂质X可以作为盐酸利匹韦林杂质对照品,为盐酸利匹韦林的质量研究提供了依据。 Taking(E)-3-(4-amino-3,5-dimethylphenyl)acrylonitrile as a starting material, more cis-isomer Z of rilpivirine hydrochloride(about 50%) and impurity X(about 5%) can be obtained by introducing electron-absorbing groups such as trifluoroacetyl group on the amino nitrogen atom.Moreover, the structures of the cis-isomer Z and impurity X are confirmed by ~1HNMR,13CNMR,and MS,and their purity can reach more than 98% by HPLC detection.Impurity X can be used as the impurity reference of rilpivirine hydrochloride.The study provides a basis for the quality study of rilpivirine hydrochloride.
作者 郭建锋 肖琳霞 屈钦 汪淼 田峦鸢 李莉娥 刘敏 GUO Jianfeng;XIAO Linxia;QU Qin;WANG Miao;TIAN Luanyuan;LI Lie;LIU Min(Yichang Renfu Pharmaceutical Co.,Ltd.,Yichang 443000,China)
出处 《化学与生物工程》 CAS 2023年第2期65-68,共4页 Chemistry & Bioengineering
关键词 盐酸利匹韦林 合成 吸电子基团 顺式异构体 杂质 rilpivirine hydrochloride synthesis electron-absorbing group cis-isomer impurity
  • 相关文献

参考文献1

二级参考文献16

  • 1DAS K, BAUMAN J, CLARK A. et al. High-resolution struc- tures of HIV-1 reverse transcriptase/TMC278 complexes: Strate- gic flexibility explains potency against resistance mutations [ J ]. Proc Natl Acad Sci, 2008, 105: 1466-1471. 被引量:1
  • 2CRAUWELS H, VINGERHOETS J, RYAN R, et al. Pharmaco- netic parameters of once-daily rilpivirine following administration of efavirenz in healthy subjects [ J ]. Antivir Ther, 2012,17 (3):439-446. 被引量:1
  • 3DE BETHUNE M, ANDRIES K, AZIJN H, et al. TMC-278, a new potent NNRTI, with an increased barrier to resistance and good pharmacokinetic profile [ R]. 12th Conference on Retrovir- uses and Opportunistic Infections ; 22-25 February 2005, Boston, MA. 被引量:1
  • 4DICKINSON L, KHOO S, BACK D. Pharmacokineties and drug- drug interactions of antiretrovirals: An update [ J]. Antiviral Res, 2010,85 ( 1 ) : 176-189. 被引量:1
  • 5JAYAWEERA D, DILANCHIAN P. RILPIVIRINE. First-line treatment of HIV infection : Efavirenz is better documented [ J]. Prescrire lnt, 2012, 21 (132) :262-265. 被引量:1
  • 6COHEN C J, ANDRADE-VILLANUEVA J, CLOTET B, et al. Rilpivirine versus efavirenz with two background nucleoside or nude- otide reverse transcriptase inhibitors in treatment-naive adults infec- ted with HIV-1 (THRIVE) : A phase 3, randonfised, non-inferiority trial [J]. Lancet, 2011, 378(9787) :229-237. 被引量:1
  • 7COHEN C J, MOLINA J M, CASSETYI I, et al. Week 96 effica- cy and safety of rilpivirine in treatment-nai've, HIV-1 patients in two phase III randomised trials [ J]. AIDS, 2012, 14 (3) :168- 178. 被引量:1
  • 8SHARMA M, SARAVOLATZ L D. Rilpivirine: A new non-nu- cleoside reverse transcriptase inhibitor [ J ]. J Antimicrob Che- moth, 2012, 55(2) :107-113. 被引量:1
  • 9NIMISH PATEL, CHRISTOPHER D MILLER. New option for management of HIV-1 infection in treatment-naive patients : Once- daily, fixed-dose combination of rilpivirine-emtricitabine-tenofovir [J]. HIVAIDS (Auekl), 2012, 4: 61-71. 被引量:1
  • 10CALVIN J. COHEN, JEAN-MICHEL MOLINA, PEDRO CAHN, et al. Efficacy and safety of rilpivifine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: Pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials [J]. Clin Sei, 2012, 60(1) :33-42. 被引量:1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部